The oral Ca/calmodulin ‐dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure

ConclusionsRA608 is the first orally administrable CaMKII inhibitor with potent efficacy in human myocytes. Moreover, oral administration potently inhibits arrhythmogenesis and attenuates HF development in micein vivo.

Source: ESC Heart Failure - July 19, 2020 Category: Cardiology Authors: Julian Mustroph, Marzena Drzymalski, Maria Baier, Steffen Pabel, Alexander Biedermann, Bernadette Memmel, Melanie Durczok, Stefan Neef, Can Martin Sag, Bernhard Floerchinger, Leopold Rupprecht, Christof Schmid, York Zausig, Guillaume B égis, Tags: Original Research Article Source Type: research